Abstract

The specific objectives of this contract are: 1) to define the acute toxicities of new anticancer agents in patients with advanced cancer; 2) to redefine the acute toxicities and pharmacokinetics of anticancer administered in combination with agents to modulate toxicity or antitumor effect; 3) to provide information on the pharmacokinetic characteristics (absorption, distribution, metabolism and elimination) and pharmacodynamics of selected antitumor agents; and 4) to determine a treatment regimen suitable for evaluation of antitumor activity in Phase II trials.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM007301-006
Application #
3607821
Study Section
Project Start
1990-05-01
Project End
1995-05-31
Budget Start
1993-06-30
Budget End
1994-07-31
Support Year
Fiscal Year
1993
Total Cost
Indirect Cost

  Institution

Name
University of Chicago
Department
Type
Schools of Medicine
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637

  Publications

Klein, Cheri Enders; Gupta, Elora; Reid, Joel M et al. (2002) Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther 72:638-47
Gordon, E J; Daugherty, C K (2001) Referral and decision making among advanced cancer patients participating in Phase I trials at a single institution. J Clin Ethics 12:31-8
Mani, S; Kugler, J W; Sciortino, D F et al. (1998) Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. Ann Oncol 9:1035-7
Mani, S; Kugler, J W; Knost, J A et al. (1998) Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Invest New Drugs 16:275-8
Vogelzang, N J; Mani, S; Schilsky, R L et al. (1998) Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res 4:929-34
Gupta, E; Mick, R; Ramirez, J et al. (1997) Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15:1502-10
Daugherty, C K; Siegler, M; Ratain, M J et al. (1997) Learning from our patients: one participant's impact on clinical trial research and informed consent. Ann Intern Med 126:892-7
Soliven, B; Dhand, U K; Kobayashi, K et al. (1997) Evaluation of neuropathy in patients on suramin treatment. Muscle Nerve 20:83-91
Ratain, M J; Mick, R; Janisch, L et al. (1996) Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics 6:93-101
Kobayashi, K; Weiss, R E; Vogelzang, N J et al. (1996) Mineralocorticoid insufficiency due to suramin therapy. Cancer 78:2411-20

Showing the most recent 10 out of 22 publications